XML 20 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Cash flows provided by operating activities    
Net income (loss) $ 1,422 $ (4,705)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Write-down of capitalized software development costs 0 1,538
Depreciation 383 493
Amortization of definite-lived intangible assets 289 494
Amortization of capitalized software development costs 408 341
Change in fair value of contingent consideration (207) 849
Stock-based compensation expense 1,550 541
Loss on equity method investments 0 233
Loss on derivative instruments, net 18 40
Deferred income taxes 123 171
Gain (Loss) on Sale of Assets and Asset Impairment Charges 3 0
Changes in assets and liabilities    
Contract receivables, net (6,078) 2,530
Prepaid expenses and other assets (1,249) (501)
Accounts payable, accrued compensation and accrued expenses 961 (947)
Billings in excess of revenue earned 12,257 (552)
Accrued warranty (465) 171
Other liabilities 737 320
Net cash provided by operating activities 10,152 1,016
Cash flows from investing activities:    
Capital expenditures (79) (277)
Proceeds from Sale of Property, Plant, and Equipment 30 0
Capitalized software development costs (245) (1,610)
Restrictions of cash as collateral under letters of credit 0 (1,222)
Releases of cash as collateral under letters of credit 2,408 1,876
Net cash provided by (used in) investing activities 2,114 (1,233)
Cash flows from financing activities:    
Payments on line of credit 0 (339)
Proceeds from issuance of common stock on the exercise of stock options 833 23
RSUs withheld to pay taxes (584) 0
Contingent consideration payments to Hyperspring, LLC (1,421) (1,700)
Net cash used in financing activities (1,172) (2,016)
Effect of exchange rate changes on cash (431) (266)
Net increase (decrease) in cash and cash equivalents 10,663 (2,499)
Cash and cash equivalents at beginning of year 11,084 13,583
Cash and cash equivalents at end of period $ 21,747 $ 11,084